Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Short-term treatment of hypertension when oral therapy is not feasible or desirable
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion of 5 mg/hour initially, titrated by 2.5 mg/hour every 15 minutes up to 15 mg/hour for acute hypertension. Typical infusion rate: 5-15 mg/hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life is approximately 2-4 hours in healthy adults; prolonged to about 7 hours in cirrhosis or hepatic impairment.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Hepatic via CYP3A4 and CYP2C8
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 35% of metabolites.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
>95% bound primarily to albumin.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.6-1.5 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100%; Oral: approximately 35% due to extensive first-pass metabolism.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl >30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific dose reduction recommended but monitor closely.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
In Child-Pugh Class A or B, reduce initial infusion rate to 2.5 mg/hour and titrate slowly. Avoid use in Child-Pugh Class C due to significant accumulation.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
For children ≥2 years: Initial intravenous infusion of 0.5-1 mcg/kg/minute, titrate by 0.5 mcg/kg/minute every 5-15 minutes to desired effect. Maximum: 5 mcg/kg/minute.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Initiate at lower end of dosing range (2.5-5 mg/hour intravenous infusion) and titrate slowly due to increased sensitivity and potential for hypotension.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA boxed warning.
None
Use caution in patients with heart failure, hepatic impairment, renal impairment, or acute cardiovascular disease. May cause hypotension, tachycardia, and peripheral edema. Monitor blood pressure and heart rate during infusion. Avoid abrupt discontinuation. Use with caution in patients with coronary artery disease due to possible reflex tachycardia.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to nicardipine or any component,Advanced aortic stenosis,Patients with known hypersensitivity to dihydropyridine calcium channel blockers
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Grapefruit products (fruit and juice) should be avoided as they inhibit CYP3A4 metabolism of nicardipine, increasing its serum concentration and risk of hypotension and other adverse effects. No other significant food interactions known.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
NICARDIPINE (CARDENE) - Teratogenic risk profile: First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: No increased risk of major malformations reported; potential for maternal hypotension and fetal hypoxia with high doses. Avoid use in pregnancy-induced hypertension unless benefit outweighs risk.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
NICARDIPINE (CARDENE) - Lactation summary: Excreted into breast milk in low concentrations (M/P ratio approximately 0.7); no adverse effects reported in infants. Use with caution, especially in preterm infants due to immature hepatic metabolism.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
NICARDIPINE (CARDENE) - Dosing adjustments in pregnancy: Pregnancy increases volume of distribution and clearance; dose requirements may be higher. Start at low end of dosing range and titrate to effect, monitoring for hypotension. Intravenous infusion: 5 mg/hour initially, increased by 2.5 mg/hour every 5-15 minutes to a maximum of 15 mg/hour.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Cardene (nicardipine) IV is a dihydropyridine calcium channel blocker used for short-term treatment of hypertension when oral therapy is not feasible. It has rapid onset and is titratable. Monitor for hypotension, reflex tachycardia, and peripheral edema. Use with caution in patients with aortic stenosis, coronary artery disease, or heart failure. It is compatible with 0.83% sodium chloride; avoid adding other drugs. Protect from light. Titrate based on blood pressure response. Hypotension may be profound in volume-depleted patients.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is given intravenously to lower your blood pressure. Report any dizziness, lightheadedness, or fainting immediately.,You may experience swelling in your legs or ankles. Notify your healthcare provider if this becomes bothersome.,Avoid sudden changes in position (e.g., standing up quickly) to prevent falls.,Do not consume grapefruit or grapefruit juice while on this medication, as it can increase the drug's effects and risk of side effects.,Inform your doctor if you have a history of liver or kidney disease, heart problems, or if you are pregnant or breastfeeding.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is a Electrolyte that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is: Intravenous infusion of 5 mg/hour initially, titrated by 2.5 mg/hour every 15 minutes up to 15 mg/hour for acute hypertension. Typical infusion rate: 5-15 mg/hour.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category A/B. NICARDIPINE (CARDENE) - Teratogenic risk profile: First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimeste. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.